2019
Immune reaction by cytoreductive prostatectomy.
Lee G, Srivastava A, Kwon Y, Kim I. Immune reaction by cytoreductive prostatectomy. American Journal Of Clinical And Experimental Urology 2019, 7: 64-79. PMID: 31139701, PMCID: PMC6526355.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerCytoreductive prostatectomyProstate cancerMetastatic diseaseCastration-resistant prostate cancerCommon non-cutaneous cancerCastration-resistant diseaseResistant prostate cancerMale cancer deathsNon-cutaneous cancerNovel treatment strategiesImmunologic changesAdvanced diseaseOncologic outcomesSurvival benefitCombinational immunotherapyCancer deathTreatment modalitiesHormonal manipulationMetastatic cancerTreatment strategiesImmune reactionsSurvival rateEffective cureCancer
2015
Pathologic findings in patients who underwent robot-assisted radical prostatectomy following active surveillance: a prospective study in a single center.
Ha Y, Yu J, Patel N, Hassanzadeh Salmasi A, Parihar J, Kwon T, Kim W, Kim I. Pathologic findings in patients who underwent robot-assisted radical prostatectomy following active surveillance: a prospective study in a single center. Minerva Urologica E Nefrologica 2015, 67: 1-9. PMID: 25664959.Peer-Reviewed Original ResearchConceptsRobot-assisted radical prostatectomyRadical prostatectomyActive surveillanceAdvanced diseaseUnderwent robot-assisted radical prostatectomyLow-risk prostate cancerLower prostate volumePSA density levelsLow-risk diseaseActive surveillance cohortOrgan-confined diseaseSpecimens of patientsAdvanced pathologic featuresProspective cohortAdditional patientsPathologic featuresPathologic findingsProstate volumeSingle centerProspective studyGleason scoreSurveillance cohortDefinitive interventionClinicopathological resultsPathologic analysis
2014
Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review)
FAIENA I, SINGER E, PUMILL C, KIM I. Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review). International Journal Of Oncology 2014, 45: 2193-2198. PMID: 25340386, PMCID: PMC4215584, DOI: 10.3892/ijo.2014.2656.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerProstate cancerMetastatic diseaseSystemic therapyRadical prostatectomyPotential oncologic benefitsDefinitive local therapyPrior radical prostatectomyLow-stage cancersNew surgical paradigmOncologic benefitAcceptable morbidityAdvanced diseaseMetastatic settingLocal therapySimilar morbidityCancer deathKidney cancerStage cancerBetter survivalSurgical paradigmPatientsCancerPotential benefitsTherapy
2013
Increased Incidence of Pathologically Nonorgan Confined Prostate Cancer in African-American Men Eligible for Active Surveillance
Ha Y, Salmasi A, Karellas M, Singer E, Kim J, Han M, Partin A, Kim W, Lee D, Kim I. Increased Incidence of Pathologically Nonorgan Confined Prostate Cancer in African-American Men Eligible for Active Surveillance. Urology 2013, 81: 831-836. PMID: 23465143, PMCID: PMC3978180, DOI: 10.1016/j.urology.2012.12.046.Peer-Reviewed Original ResearchConceptsNational Comprehensive Cancer NetworkAA menRadical prostatectomyActive surveillanceProstate cancerNCCN criteriaBiopsy coresAS criteriaAS inclusion criteriaFinal surgical pathologyComprehensive Cancer NetworkPositive biopsy coresDatabase of menWorse clinicopathological featuresAfrican American menPathological upstagingAdvanced diseaseIndependent predictorsPathologic characteristicsClinicopathological featuresPreoperative PSAClinicopathologic findingsWA patientsInclusion criteriaPositive cores
2011
RUNX3 methylation as a predictor for disease progression in patients with non‐muscle‐invasive bladder cancer
Yan C, Kim Y, Ha Y, Kim I, Kim Y, Yun S, Moon S, Bae S, Kim W. RUNX3 methylation as a predictor for disease progression in patients with non‐muscle‐invasive bladder cancer. Journal Of Surgical Oncology 2011, 105: 425-430. PMID: 22311819, DOI: 10.1002/jso.22087.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overCarcinoma in SituCarcinoma, Transitional CellChildCore Binding Factor Alpha 3 SubunitDisease ProgressionDNA MethylationDNA, NeoplasmFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansLymphatic MetastasisMaleMiddle AgedNeoplasm GradingNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPolymerase Chain ReactionPrognosisPromoter Regions, GeneticSurvival RateUrinary Bladder NeoplasmsYoung AdultConceptsDisease progressionRUNX3 methylation statusRUNX3 methylationTumor stageBladder cancerTumor gradeNMIBC progressionInvasive bladder cancer patientsWorse progression-free survivalProgression-free survivalInvasive bladder cancerPoor clinical outcomeKaplan-Meier estimatesBladder cancer patientsMethylation statusNumber of tumorsHypermethylation of RUNX3Methylation-specific polymerase chain reactionNMIBC samplesAdvanced diseaseClinical outcomesClinicopathological characteristicsIndependent predictorsCancer patientsG3 tumors